63 results
425
RPHM
Reneo Pharmaceuticals Inc
13 May 24
Business combination disclosure
9:38am
”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (a) Merger Sub I will merge … .
Section 2.3 Closing. Unless this Agreement is earlier terminated pursuant to the provisions of Article IX, and subject to the satisfaction or waiver
8-K
EX-10.4
RPHM
Reneo Pharmaceuticals Inc
13 May 24
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
9:14am
or other securities of the Company prior to the Closing or issued pursuant to the Mergers.
2.2 Closing
Subject to the satisfaction or waiver … with or closed to the satisfaction of the relevant governmental authority, and, to the knowledge of the Company, neither the FDA nor any other
8-K
EX-99.1
RPHM
Reneo Pharmaceuticals Inc
13 May 24
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
9:14am
of the combined company on Nasdaq, and satisfaction of other customary closing conditions.
Including proceeds from the concurrent PIPE financing, the combined
8-K
EX-10.2
RPHM
Reneo Pharmaceuticals Inc
13 May 24
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
9:14am
of time in excess of 60 days, the satisfaction of any conditions, the occurrence of any event or any combination of the foregoing).
6. Waiver
8-K
EX-10.1
RPHM
Reneo Pharmaceuticals Inc
13 May 24
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
9:14am
or only after the passage of time, including the passage of time in excess of 60 days, the satisfaction of any conditions, the occurrence of any event
8-K
4ghu54hf5x9 bt6jucy
13 May 24
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
9:14am
8-K
EX-2.1
0imevoa6zmsjkyctf
13 May 24
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
9:14am
424B5
qozr1jfe4lh
13 Nov 23
Prospectus supplement for primary offering
4:58pm